Denali Interventional Study

This is a multicenter, open-label study to study the safety and characteristics of DNL310, an investigational drug designed to treat both the body and brain manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome). The plan is for each participant to start at a low dose and increase over time until a final dose is achieved. Blood, urine and CSF samples will be taken, and tests and assessments will be done to see how your child is doing in the study.